Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer

Authors: Hiroharu Yamashita, Joji Kitayama, Nobuko Kanno, Yutaka Yatomi, Hirokazu Nagawa

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Abnormal hemostasis in cancer patients has previously been described, however the correlation between the plasma fibrinogen level and cancer metastasis and prognosis has not been reported in a large-scale clinical study.

Methods

Preoperative plasma fibrinogen levels were retrospectively examined in 405 patients who underwent surgery for advanced gastric cancer. The association of fibrinogen levels with clinical/pathological findings and clinical outcome was evaluated.

Results

There was a positive correlation between plasma fibrinogen levels and the depth of invasion (p < 0.05). Hyperfibrinogenemia (>310 mg/dl) was independently associated with lymph node (Odds Ratio; 2.342, P = 0.0032) and liver (Odds Ratio; 2.933, P = 0.0147) metastasis, not with peritoneal metastasis in this series. Patients with hyperfibrinogenemia showed worse clinical outcome in T2 gastric cancer, however, there was no correlation of plasma fibrinogen level with prognosis in T3/T4 gastric cancer.

Conclusion

Our results might support the idea that hyperfibrinogenemia can augment lymphatic and hematogeneous metastasis of advanced gastric cancer, which is major determinant of the prognosis in T2 gastric cancer. Therefore, in the situation without peritoneal involvement, hyperfibrinogenemia is a useful biomarker to predict the possible metastasis and worse clinical outcome in T2 gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Trousseau A: Phlegmasia alba dolens. Clinique Medicale de L'Hotel Dieu de Paris. 1865, Paris , Balliere, 654-656. 2nd
2.
Sun NC, McAfee WM, Hum GJ, Weiner JM: Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol. 1979, 71 (1): 10-16.CrossRefPubMed
3.
Luzzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol. 1990, 17 (2): 147-159.PubMed
4.
Lopez Y, Paloma MJ, Rifon J, Cuesta B, Paramo JA: Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states. Thromb Res. 1999, 93 (2): 71-78. 10.1016/S0049-3848(98)00165-0.CrossRefPubMed
5.
Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T: Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002, 9 (3): 287-291. 10.1245/aso.2002.9.3.287.CrossRefPubMed
6.
Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, Takeda A, Gunji Y, Ochiai T: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004, 198 (5): 737-741. 10.1016/j.jamcollsurg.2004.01.022.CrossRefPubMed
7.
Costantini V, Zacharski LR, Moritz TE, Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb Haemost. 1990, 64 (4): 501-505.PubMed
8.
Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA: Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int. 2000, 86 (3): 203-207. 10.1046/j.1464-410x.2000.00792.x.CrossRefPubMed
9.
Hernandez E, Donohue KA, Anderson LL, Heller PB, Stehman FB: The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000, 78 (2): 137-142. 10.1006/gyno.2000.5838.CrossRefPubMed
10.
Unsal E, Atalay F, Atikcan S, Yilmaz A: Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med. 2004, 98 (2): 93-98. 10.1016/j.rmed.2003.07.001.CrossRefPubMed
11.
Buccheri G, Torchio P, Ferrigno D: Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer. 2003, 97 (12): 3044-3052. 10.1002/cncr.11432.CrossRefPubMed
12.
Oya M, Akiyama Y, Okuyama T, Ishikawa H: High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001, 31 (8): 388-394. 10.1093/jjco/hye075.CrossRefPubMed
13.
Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C: Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004, 101 (1): 77-82. 10.1002/cncr.20336.CrossRefPubMed
14.
15.
Lee JH, Ryu KW, Kim S, Bae JM: Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology. 2004, 51 (60): 1860-1863.PubMed
16.
Yamashita H, Kitayama J, Nagawa H: Hyperfibrinogenemia is a useful predictor for lymphatic metastasis in human gastric cancer. Jpn J Clin Oncol. 2005, 35 (10): 595-600. 10.1093/jjco/hyi150.CrossRefPubMed
17.
Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000, 96 (10): 3302-3309.PubMed
18.
Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL: Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res. 2002, 62 (23): 6966-6972.PubMed
19.
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL: Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005, 105 (1): 178-185. 10.1182/blood-2004-06-2272.CrossRefPubMed
20.
Japanese Gastric Cancer A: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1998, 1 (1): 10-24. 10.1007/PL00011681.CrossRef
21.
Ernst E, Koenig W: Fibrinogen and cardiovascular risk. Vasc Med. 1997, 2 (2): 115-125.PubMed
22.
Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC: Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr. 1998, 128 (8): 1355-1360.PubMed
23.
Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM: Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer. 2001, 84 (12): 1602-1609. 10.1054/bjoc.2001.1720.CrossRefPubMedPubMedCentral
24.
Moriguchi S, Maehara Y, Korenaga D, Sugimachi K, Nose Y: Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol. 1992, 1 (5): 341-346. 10.1016/0960-7404(92)90034-I.CrossRefPubMed
25.
Otsuji E, Kuriu Y, Ichikawa D, Okamoto K, Ochiai T, Hagiwara A, Yamagishi H: Time to death and pattern of death in recurrence following curative resection of gastric carcinoma: analysis based on depth of invasion. World J Surg. 2004, 28 (9): 866-869. 10.1007/s00268-004-7359-7.CrossRefPubMed
26.
Yano H, J. K, Hatano K, Tsuno N, Osada T, Watanabe T, Tsuruo T, Muto T, Nagawa H: Clustered cancer cells show a distinct adhesion behavior from single cell form under physiological shear conditions. J Exp Clin Cancer Res. 2001, 20 (3): 407-412.
27.
Nieswandt B, Hafner M, Echtenacher B, Mannel DN: Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999, 59 (6): 1295-1300.PubMed
28.
Iversen LH, Thorlacius-Ussing O: Relationship of coagulation test abnormalities to tumour burden and postoperative DVT in resected colorectal cancer. Thromb Haemost. 2002, 87 (3): 402-408.PubMed
29.
Roselli M, Mineo TC, Basili S, Mariotti S, Martini F, Bellotti A, Ambrogi V, Spila A, D'Alessandro R, Gazzaniga PP, Guadagni F, Ferroni P: Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb Haemost. 2003, 89 (1): 177-184.PubMed
30.
Di Micco P, Romano M, Niglio A, Nozzolillo P, Federico A, Petronella P, Nunziata L, Di Micco B, Torella R: Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2001, 33 (7): 546-550. 10.1016/S1590-8658(01)80105-5.CrossRefPubMed
31.
Wojtukiewicz MZ, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Rozanska-Kudelska M, Kisiel W, Kudryk BJ: Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. Thromb Res. 2000, 97 (5): 335-342. 10.1016/S0049-3848(99)00169-3.CrossRefPubMed
32.
Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C: Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy. Scand J Gastroenterol. 1994, 29 (6): 516-521.CrossRefPubMed
33.
Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, Mosesson MW, Lord S, Weiler H: Cause-effect relation between hyperfibrinogenemia and vascular disease. Blood. 2004, 103 (5): 1728-1734. 10.1182/blood-2003-08-2886.CrossRefPubMed
Metadata
Title
Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer
Authors
Hiroharu Yamashita
Joji Kitayama
Nobuko Kanno
Yutaka Yatomi
Hirokazu Nagawa
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-147

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue

Research article

Anthropometric measures in relation to Basal Cell Carcinoma: a longitudinal study

Research article

Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas

Research article

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

Research article

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

Research article

Increased mRNA expression levels of ERCC1, OGG1 and RAIin colorectal adenomas and carcinomas

Research article

High-risk human papilloma virus (HPV) and survival in patients with esophageal carcinoma: a pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits